超重、肥胖和糖尿病:全球趋势和更美好的未来?

IF 1.9
Health systems and reform Pub Date : 2025-12-31 Epub Date: 2025-06-23 DOI:10.1080/23288604.2025.2518797
Barbara McPake
{"title":"超重、肥胖和糖尿病:全球趋势和更美好的未来?","authors":"Barbara McPake","doi":"10.1080/23288604.2025.2518797","DOIUrl":null,"url":null,"abstract":"<p><p>The related overweight, obesity and diabetes epidemics are more than five decades old and have progressed inexorably. A billion people in the world are now obese, and nearly a billion are diabetic. The belief that diabetes is caused by overweight and obesity has led to public health advice focused on lifestyle change as the main preventive approach. This advice has shifted over time, and some parts of the public health community have started to switch from a lifestyle to an environmental perspective. There is a growing but not yet conclusive evidence base that rather than diabetes being caused by overweight and obesity, the three conditions have a common third cause, and difficulties in controlling weight and blood glucose emerge in tandem. New classes of medications, including semaglutides and tirzepatides, effectively address these processes. They are in the early stages of development but have accumulated a safety record over the last decade. They are largely currently available only to those who can afford their relatively high cost, but new generations of related medications are capable of becoming lower cost, and wider access to them could transform the overweight, obesity and diabetes pandemics. There is a marked absence of enthusiasm for their potential role in the public health community. This appears to reflect stigmatized attitudes to overweight and obesity, which contrast with attitudes to diabetes. A successful medical treatment may be the key to resolving that stigma and reversing the three pandemics.</p>","PeriodicalId":73218,"journal":{"name":"Health systems and reform","volume":"11 1","pages":"2518797"},"PeriodicalIF":1.9000,"publicationDate":"2025-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Overweight, Obesity and Diabetes: Global Trends and a Better Future?\",\"authors\":\"Barbara McPake\",\"doi\":\"10.1080/23288604.2025.2518797\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The related overweight, obesity and diabetes epidemics are more than five decades old and have progressed inexorably. A billion people in the world are now obese, and nearly a billion are diabetic. The belief that diabetes is caused by overweight and obesity has led to public health advice focused on lifestyle change as the main preventive approach. This advice has shifted over time, and some parts of the public health community have started to switch from a lifestyle to an environmental perspective. There is a growing but not yet conclusive evidence base that rather than diabetes being caused by overweight and obesity, the three conditions have a common third cause, and difficulties in controlling weight and blood glucose emerge in tandem. New classes of medications, including semaglutides and tirzepatides, effectively address these processes. They are in the early stages of development but have accumulated a safety record over the last decade. They are largely currently available only to those who can afford their relatively high cost, but new generations of related medications are capable of becoming lower cost, and wider access to them could transform the overweight, obesity and diabetes pandemics. There is a marked absence of enthusiasm for their potential role in the public health community. This appears to reflect stigmatized attitudes to overweight and obesity, which contrast with attitudes to diabetes. A successful medical treatment may be the key to resolving that stigma and reversing the three pandemics.</p>\",\"PeriodicalId\":73218,\"journal\":{\"name\":\"Health systems and reform\",\"volume\":\"11 1\",\"pages\":\"2518797\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2025-12-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Health systems and reform\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/23288604.2025.2518797\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/6/23 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Health systems and reform","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/23288604.2025.2518797","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/23 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

相关的超重、肥胖和糖尿病流行已经有50多年的历史了,而且一直在无情地发展。现在世界上有10亿人肥胖,近10亿人患有糖尿病。由于认为糖尿病是由超重和肥胖引起的,公共卫生建议将改变生活方式作为主要的预防方法。随着时间的推移,这种建议已经发生了变化,公共卫生界的一些人已经开始从一种生活方式转向一种环境观点。越来越多但尚未结论性的证据表明,糖尿病不是由超重和肥胖引起的,这三种疾病有一个共同的第三个原因,而且控制体重和血糖的困难是同时出现的。新型药物,包括半聚肽和替西帕肽,有效地解决了这些问题。它们还处于开发的早期阶段,但在过去十年中积累了良好的安全记录。目前,这些药物大多只提供给那些能够负担得起相对较高费用的人,但新一代相关药物的成本可能会降低,而且更广泛地获得这些药物可能会改变超重、肥胖和糖尿病的流行。人们对它们在公共卫生界的潜在作用明显缺乏热情。这似乎反映了对超重和肥胖的污名化态度,这与对糖尿病的态度形成对比。成功的医学治疗可能是消除这种耻辱和扭转三大流行病的关键。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Overweight, Obesity and Diabetes: Global Trends and a Better Future?

The related overweight, obesity and diabetes epidemics are more than five decades old and have progressed inexorably. A billion people in the world are now obese, and nearly a billion are diabetic. The belief that diabetes is caused by overweight and obesity has led to public health advice focused on lifestyle change as the main preventive approach. This advice has shifted over time, and some parts of the public health community have started to switch from a lifestyle to an environmental perspective. There is a growing but not yet conclusive evidence base that rather than diabetes being caused by overweight and obesity, the three conditions have a common third cause, and difficulties in controlling weight and blood glucose emerge in tandem. New classes of medications, including semaglutides and tirzepatides, effectively address these processes. They are in the early stages of development but have accumulated a safety record over the last decade. They are largely currently available only to those who can afford their relatively high cost, but new generations of related medications are capable of becoming lower cost, and wider access to them could transform the overweight, obesity and diabetes pandemics. There is a marked absence of enthusiasm for their potential role in the public health community. This appears to reflect stigmatized attitudes to overweight and obesity, which contrast with attitudes to diabetes. A successful medical treatment may be the key to resolving that stigma and reversing the three pandemics.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信